ot) 2x Approvals + Profitability in 2012
Nuvo is definitely one of the most undervalued stock in the US $ Canada Biotech Sector . Nuvo is almost a unknown Gem thats the only problem with this Goldmine but this will change soon with a US listing which will bring a lot of new investors to this Goldmine .
Nuvo has already 2 Products (Pennsaid +Synera) on the Market .The next Product (Pliaglis) will enter the US and EU Market by mid 2012 .Nuvo will get $ 8 M milestone payment upon EU launch from Top-Partner Galderma who holds the worldwide rights for Pliaglis .(MORE INFOS IN THEIR PRESENTATION LINK BELOW) .
Nuvo will be profitable by late 2012 or early 2013 the future looks very good for this Goldmine .
Market cap of 36 M is RIDICULOUS Nuvo deserves a Market cap of minimum $150 M or around 0.30 per share .
Fantastic entry point at this HUGE bargain level .Patience will payoff big time here .GLTA
Nuvo Research (NRI.TO)
Market Cap : $39.4 M
Cash: $18.1 M
Price 0.07 $
NO DEBT
Presentation Jan 2012
https://www.nuvoresearch.com/investors/documents/presentations/2012-01-04%20Nuvo%20IR%20Presentation%20January_2012.pdf
Insider Activity
https://canadianinsider.com/node/7?menu_tickersearch=nri
LOTS OF GOOD NEWS COMING TO PUSH THIS GOLDMINE WAYY HIGHER ...
2012 Milestones
Growing Pennsaid U.S. sales = higher royalty revenue
Covidien sNDA for Pennsaid 2%
Pliaglis approval and launch in the U.S. and E.U. = new royalty
revenue and milestone payments ( 15% royalties + $8 M milestone upon EU launch )
Relaunch Synera in the U.S. and expand in the E.U.
?? Announce action plan for WF10 development